The Asia-Pacific Dengue Prevention Board organized a meeting (Kuala Lumpur, Malaysia, 1–2 June 2016) to highlight points for consideration about CYD-TDV vaccine introduction and to define the most useful tools and approaches for dengue endemic countries to develop policies.
We invite you to read the full report on the "Development of Dengue Vaccines: Issues relating to dengue vaccine introduction in light of the WHO SAGE recommendations" here.
Since the early 1990s much progress has been made in developing dengue vaccines. The most advanced candidates include the following approaches:
- Live attenuated vaccines, prepared through advanced genetic techniques, including chimerization or sequence deletion.
- Purified inactivated vaccines.
- Subunit vaccines, which use a portion of the envelope protein of dengue virus.
Other vaccines still in pre-clinical phases of development include plasmid DNA and vectored approaches.